NRx Pharmaceuticals (NASDAQ:NRXP) Receives “Buy” Rating from HC Wainwright

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $19.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on NRXP. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. Ascendiant Capital Markets upped their target price on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th.

NRx Pharmaceuticals Trading Up 2.4 %

Shares of NASDAQ:NRXP opened at $1.26 on Monday. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $7.33. The company has a fifty day simple moving average of $1.39 and a 200 day simple moving average of $2.16. The firm has a market cap of $15.23 million, a PE ratio of -0.59 and a beta of 1.27.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC purchased a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned 0.14% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.